These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35477179)

  • 21. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
    Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
    Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
    O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
    Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
    Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
    Zhu F; Crombie JL; Ni W; Hoang NM; Garg S; Hackett L; Chong SJF; Collins MC; Rui L; Griffin J; Davids MS
    Haematologica; 2024 Jan; 109(1):186-199. PubMed ID: 37534528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
    Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
    Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
    [No Abstract]   [Full Text] [Related]  

  • 32. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
    Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
    Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
    Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.
    Nguyen TH; Koneru B; Wei SJ; Chen WH; Makena MR; Urias E; Kang MH; Reynolds CP
    Mol Cancer Ther; 2019 Dec; 18(12):2270-2282. PubMed ID: 31484706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma.
    Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM
    Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression.
    Ning N; Zhang S; Wu Q; Li X; Kuang D; Duan Y; Xia M; Liu H; Weng J; Ba H; Tang Z; Cheng X; Mei H; Huang L; Ao Q; Wang G; Hu Y; Laurence A; Wang J; Wang G; Yang XP
    Theranostics; 2022; 12(12):5537-5550. PubMed ID: 35910796
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.